Aptargroup Inc
F:AGT

Watchlist Manager
Aptargroup Inc Logo
Aptargroup Inc
F:AGT
Watchlist
Price: 103.7 EUR 0.68% Market Closed
Market Cap: €6.9B

Aptargroup Inc
Investor Relations

AptarGroup makes packaging and dispensing components that help people use products in controlled, convenient ways. Its products include pumps, spray nozzles, valves, closures, and other specialized parts used on bottles, tubes, and containers. The company sells these parts to consumer brands and manufacturers in personal care, beauty, food, home care, and prescription medicine. AptarGroup earns money mainly by supplying these components to large packaged-goods companies and drug makers. Customers pay for the parts that go into their finished products, and Aptar also works with them on design and engineering so the dispensing system fits the product and the production line. In healthcare, its products help deliver medicines more accurately and safely, which makes it a key supplier in the drug packaging chain. What sets Aptar apart is that it sits between the brand owner and the final package: it does not sell the shampoo, lotion, or medicine itself, but the device that makes the product easy and reliable to use. That gives it a role in many everyday products while tying it to recurring demand for replacement packaging and new product launches. The business is built around highly engineered parts, long customer relationships, and steady repeat orders from manufacturers that need dependable packaging components.

Show more
Loading...
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare
Last Earnings Call
Fiscal Period
Q1 2026
Call Date
May 1, 2026
AI Summary
Q1 2026

Quarter: Aptar said Q1 played out largely as expected, with reported sales up 11% but core sales flat because currency helped reported growth while underlying demand was mixed.

Pharma drag: Emergency medicine destocking remained the main headwind, cutting Pharma core sales by 3% and prescription core sales by 5%, but management said the full-year $65 million decline estimate is still tracking.

Growth pockets: Demand stayed healthy in GLP-1s, biologics, systemic nasal drug delivery, injectables, ophthalmic dispensing and several beauty and personal care applications.

Margins: Adjusted EBITDA rose to $189 million, but margin declined to 19.2% as Beauty and Closures were hurt by product mix, maintenance issues, weather-related plant shutdowns and a minority investment write-off.

Outlook: Management expects a solid Q2, with prescription excluding emergency medicine returning to strong growth, Beauty improving, and Closures recovering sequentially; Q2 adjusted EPS guidance was $1.32 to $1.40.

Costs: Aptar said the Middle East conflict is creating higher input costs, especially raw materials, transportation and energy, but the company is largely passing those increases through to customers.

Key Financials
Reported sales
11%
Core sales
flat
Adjusted EBITDA
$189 million
Adjusted EBITDA margin
19.2%
Adjusted earnings per share
$1.19
Pharma core sales
down 1%
Emergency medicine sales decline
$65 million
Emergency medicine impact on Pharma core sales
3%
Prescription core sales
down 10%
Consumer health care core sales
up 4%
Injectables core sales
up 20%
Active material science solutions core sales
down 1%
Pharma adjusted EBITDA margin
33.3%
Beauty core sales
up 3%
Beauty adjusted EBITDA margin
11.1%
Closures core sales
flat
Closures adjusted EBITDA margin
13.1%
Consolidated gross margin
down 210 basis points
SG&A as a percentage of sales
17.1%
SG&A legal expenses
$4 million
Interest expense
$17 million
Adjusted effective tax rate
22.6%
Free cash flow
$53 million
Cash from operations
$119 million
Capital expenditures
$65 million
Share repurchases
$100 million
Dividends
$31 million
Capital returned to shareholders
$131 million
Cash balance
$223 million
Net debt
$1.1 billion
Leverage ratio
1.43
Q2 adjusted earnings per share guidance
$1.32 to $1.40
Earnings Call Recording
Other Earnings Calls

Management

Mr. Stephan B. Tanda
President, CEO & Executive Director
No Bio Available
Mr. Robert W. Kuhn
Executive VP & CFO
No Bio Available
Mr. Gael Touya
President of Aptar Pharma
No Bio Available
Mr. Marc Prieur
President of Aptar Beauty
No Bio Available
Mr. Daniel Richard Ackerman
Chief Accounting Officer
No Bio Available
Ms. Mary Skafidas
Senior Vice President of Investor Relations & Communications
No Bio Available
Ms. Shiela Pallerne Vinczeller
Chief Human Resources Officer
No Bio Available
Mr. Hedi Tlili
President of Aptar Closures
No Bio Available

Contacts

Address
ILLINOIS
Crystal Lake
265 Exchange Dr Ste 100
Contacts
+18154770424.0
www.aptar.com
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett